ArticleInternational journal of hematology2026

Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines.

Naoko Ida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.